Monoamine oxidase and agitation in psychiatric patients

Matea Nikolac Perkovic1, Dubravka Svob Strac1, Gordana Nedic Erjavec1

  • 1Rudjer Boskovic Institute, Division of Molecular Medicine, Bijenicka cesta 54, 10000 Zagreb, Croatia.

Insights

Increased platelet monoamine oxidase-B (MAO-B) activity is linked to severe agitation in individuals with schizophrenia or conduct disorder. Genetic variations in MAOA and MAOB genes were not associated with agitation in this study group.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Genetics

Background:

  • Monoamine oxidase (MAO) enzymes regulate neurotransmitters, impacting psychiatric disorders and behavior.
  • Platelet MAO-B activity and MAO gene variants are implicated in aggression and antisocial traits.

Purpose of the Study:

  • To investigate the association between platelet MAO-B activity, MAOB rs1799836 polymorphism, and MAOA uVNTR polymorphism with severe agitation.

Main Methods:

  • Studied 363 Caucasian males with schizophrenia or conduct disorder.
  • Assessed platelet MAO-B activity and specific MAOA/MAOB gene polymorphisms.
  • Correlated findings with the presence and severity of agitation.

Main Results:

  • Severe agitation showed a significant association with higher platelet MAO-B activity.
  • Platelet MAO-B activity was also associated with smoking status.
  • No significant association was found between severe agitation and MAOB rs1799836 or MAOA uVNTR polymorphisms.

Conclusions:

  • Elevated platelet MAO-B activity may be a biomarker for severe agitation in schizophrenia and conduct disorder.
  • Specific MAO gene polymorphisms (MAOA uVNTR, MAOB rs1799836) are not directly related to severe agitation in this population.

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
764
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K